Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Maintains $371 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Sell rating on Vertex Pharmaceuticals (VRTX) with a maintained price target of $371.
April 12, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Canaccord Genuity reiterates a Sell rating on Vertex Pharmaceuticals with a price target of $371.
The reaffirmation of a Sell rating by a prominent analyst could negatively impact investor sentiment towards VRTX, potentially leading to a short-term decrease in its stock price. The maintained price target of $371 suggests that the analyst sees limited upside potential or further downside from the current trading level, reinforcing the negative outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100